Results 61 to 70 of about 49,657 (223)

Drug- Resistance- Associated Mutations and HIV Sub-Type Determination in Drug-Naïve and HIV-Positive Patients under Treatment with Antiretroviral Drugs

Medical Laboratory Journal, 2013
Background and Objective: Resistance to antiretroviral agents is a significant concern in clinical management of HIV-infected individuals. Resistance is the result of mutations that develops in the viral protein targeted by antiretroviral agents ...
H Naziri, A Tabarraei, A Ghaemi, MA Davarpanah, N Javid, A Moradi   +5 more
doaj  

7-Chloro-11a-phenyl-2,3,5,10,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11-dione

Acta Crystallographica Section E, 2008
The title compound, C18H15ClN2O2, is a potential human immunodeficiency virus type-1 (HIV-1) non-nucleoside reverse transcriptase inhibitor. The pyrrolidine ring adopts an envelope and the diazepine ring a boat conformation. In the crystal structure, two
Vahan Martirosyan, Gohar Harutyunyan, Ashot Martirosyan, Armen Ayvazyan, Rafael Tamazyan   +4 more
doaj   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

1-Benzyl-6-phenylimino-5-(pyrrol-2-ylidene)hexahydropyrimidine-2,4-dione

Acta Crystallographica Section E, 2008
In the title compound, C21H20N4O2, a potential anti-human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor, the pyrrolidine ring adopts an envelope conformation, while the hydrogenated pyrimidine ring adopts a weakly ...
Ashot Martirosyan, Kristine Avagyan, Vahan Martirosyan, Armen Ayvazyan, Rafael Tamazyan   +4 more
doaj   +1 more source

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. [PDF]

, 2014
Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects.
Boger, M Sean, Currier, Judith S, Hulgan, Todd, Lake, Jordan E, Liao, Diana H, Mangili, Alexandra, McComsey, Grace A, McCreath, Heather, Milne, Ginger L, Sanchez, Stephanie C, Walmsley, Sharon L, Wanke, Christine A   +11 more
core   +3 more sources

Psychological responses to interval and continuous exercise in people living with HIV: A single‐blind, counterbalanced, crossover study

HIV Medicine, EarlyView.
Abstract Aim This study compared acute psychological responses to a single session of low‐volume high‐intensity interval exercise (HIIE‐LV), high‐volume high‐intensity interval exercise (HIIE‐HV), and moderate‐intensity continuous exercise (MICE) in people living with HIV, and healthy controls using a randomized, counterbalanced crossover design ...
Phelipe Wilde, Victor S. de Queiros, Jason R. Jaggers, Angelo Sabag, Júlio M. Alves, Elaine Fernandes, Roberto F. C. Rocha, Paulo F. de Almeida‐Neto, Ronaldo Vagner Thomatieli‐Santos, Paulo Moreira Silva Dantas   +9 more
wiley   +1 more source

EFFICACY OF COMBINED THERAPY IN CHILDREN WITH HIV INFECTION

Педиатрическая фармакология, 2010
To achieve a sustainable virus replication suppression, positive dynamics in clinical and immunologic metrics of children with HIV infection, it is necessary to use the most efficient, safe and convenient patterns of highly active antiretroviral therapy.
E.N. Simovan'yan, V.B. Denisenko
doaj   +2 more sources

Profile of etravirine in the treatment of HIV in pediatrics

Pediatric Health, Medicine and Therapeutics, 2013
Walter Dehority,1 Rolando M Viani2 1Department of Pediatrics, Division of Infectious Diseases, The University of New Mexico Health Sciences Center, University of New Mexico, Albuquerque, NM, USA; 2Department of Pediatrics, Division of Infectious Diseases,
Dehority W, Viani RM
doaj  

1-(4-Bromobenzoyl)-2-phenylpyrrolidine-2-carboxamide

Acta Crystallographica Section E, 2008
In the title compound, C18H17BrN2O2, which is a potential human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor, the pyrrolidine ring exhibits an envelope conformation. In the crystal structure, intermolecular N—
Vahan Martirosyan, Gohar Harutunyan, Ashot Martirosyan, Armen Ayvazyan, Rafael Tamazyan   +4 more
doaj   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source